Serina Therapeutics, Inc.
About Serina Therapeutics, Inc.
Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers. The company has one reportable segment relating to the research and development of its POZ platform. The segment derives its revenues from Grant revenue. Its main product candidate, SER-252 for advanced Parkinson's disease, is anticipated to enter clinical trials.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $130.0K
- Net income
- -$19.2M
- Total assets
- $7.0M
- Market cap
- $28.2M
- Operating margin
- -18478.5%
- Net margin
- -14780.8%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $130.0K
- Operating expenses
- $24.2M
- Operating income
- -$24.0M
- Income tax
- $18.0K
- Net income
- -$19.2M
- EPS (basic)
- $-1.91
- EPS (diluted)
- $-1.91
Balance sheet
- Total assets
- $7.0M
- Current assets
- $6.1M
- Total liabilities
- $7.0M
- Current liabilities
- $3.6M
- Shareholders’ equity
- -$37.0K
Cash flow
- Operating cash flow
- -$18.0M
- Investing cash flow
- -$59.0K
- Financing cash flow
- $17.4M
- Net cash flow
- -$602.0K
Statements via Polygon.io (SEC filings)
- Market cap
- $28.2M
- EPS (diluted)
- $-1.91
- Shares outstanding
- 14.8M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Mar 27, 2024
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $19.2M in FY2025.
- Revenue grew 132% from FY2024 to FY2025.
- Trading 69% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Serina Therapeutics, Inc..
Write a review
News about Serina Therapeutics, Inc.
News & sentiment via Polygon.io
